Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3159778#aggregation> ?p ?o. }
Showing items 1 to 38 of
38
with 100 items per page.
- aggregation classification "A2".
- aggregation creator B765478.
- aggregation creator B765479.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 3159778.bibtex.
- aggregation hasFormat 3159778.csv.
- aggregation hasFormat 3159778.dc.
- aggregation hasFormat 3159778.didl.
- aggregation hasFormat 3159778.doc.
- aggregation hasFormat 3159778.json.
- aggregation hasFormat 3159778.mets.
- aggregation hasFormat 3159778.mods.
- aggregation hasFormat 3159778.rdf.
- aggregation hasFormat 3159778.ris.
- aggregation hasFormat 3159778.txt.
- aggregation hasFormat 3159778.xls.
- aggregation hasFormat 3159778.yaml.
- aggregation isPartOf urn:issn:2167-583X.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "The pathogenesis of CRS: an update".
- aggregation abstract "Chronic rhinosinusitis with or without polyps affects more than 10 % of the population. In the last decennium, great progress was made in the elucidation of relevant pathomechanisms of innate and adaptive immunity and in the recognition of potential environmental and intramucosal triggers. Inflammatory pathways and triggers need to be integrated into a modern concept of disease differentiation beyond the nasal endoscope; in short, remodeling and inflammatory processes can be described, involving fibrosis versus edema, which are related to the clinical phenotype; the signatures of a number of T helper cells decide on the subsequent granulocytic tissue reactions beyond the level of neutrophils versus eosinophils. Based on those pathways, biomarkers allow the prediction of the likelihood of co-morbid asthma and individual selection of appropriate treatments, from glucocorticosteroids and immune-modulatory antibiotics to innovative approaches such as humanized monoclonal antibodies against IgE and interleukin-5. These approaches currently serve as proofofconcept tools, and will expand our armamentarium tomorrow.".
- aggregation authorList BK1135403.
- aggregation endPage "32".
- aggregation issue "1".
- aggregation startPage "25".
- aggregation volume "1".
- aggregation aggregates 3173650.
- aggregation isDescribedBy 3159778.
- aggregation similarTo s40136-012-0002-5.
- aggregation similarTo LU-3159778.